I wish you well and respect your decision. I too have wondered why estrogen levels are not being baselined and monitored with aromatase inhibitors for the same reasons. There are statistics to support the long term AI use however why not integrate monitored estrogen levels with those statistics? This could define a population that may not need to suffer through this. Maybe that has been done. I haven't searched yet. I started on letrozole 3 months ago. I'm medicating my joint pain and stiffness with fair relief from daily ibuprofen, but concerned about long-term regular use of both. I',m 63 and worried about my quality of life as well as osteoporosis. I am looking for a different oncologist and will incorporate this question in my "2nd opinion". I am also seeing a high-risk breast cancer specialist NP for another reason next week. I will discuss it with her and get back to you. I was started on letrozole prior to bilat. mastectomy with 5 tumours and now informed that I cannot get an Oncotype DX test due to my breast tumour tissue needed for this test must not have been exposed to AIs and must be at least 2 mm piece of continuous tissue. The size requirement rules out all 6 biopsy samples I am left being told if I needed any treatment, they will never know so get on with my life. have no sense of prognosis and any potential chemo I may have needed will not be considered. No special monitoring. This is another issue with studies and practice not in sync.